AUSTIN, Texas, March 12, 2020 -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery.

AUSTIN, Texas,, May 15, 2020 -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery.

AUSTIN, Texas, Feb. 28, 2020 -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery.

Take advantage of panic selling with these 7 cheap stocks.

AUSTIN, Texas, May 11, 2020 -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery.

Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” “MTEM” or the “Company”), a clinical-stage biopharmaceutical company focused on the discovery and development of the Company’s proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), today announced it has secured a debt financing facility for up to $45 million from K2 HealthVentures, a healthcare-focused specialty finance company. MTEM received a first tranche of $15 million upon closing, a portion of which has been used to repay the remaining indebtedness that was outstanding under the Company’s prior credit facility. Two subsequent tranches totaling up to $30 million will become available to MTEM, at its option, upon the achievement of certain milestones with respect to the second tranche and, subject to lender consent and certain additional conditions with respect to the third tranche.

Biotech stocks advanced in the penultimate week of the year, and the iShares NASDAQ Biotechnology Index (NASDAQ: IBB ) is on track to end the year with gains in excess of 25%. The previous week saw FDA ...

AUSTIN, Texas, Dec. 09, 2019 -- Molecular Templates, Inc., (Nasdaq: MTEM) a clinical-stage biopharmaceutical  company focused on the discovery and development of the Company’s.

If you're interested in Molecular Templates, Inc. (NASDAQ:MTEM), then you might want to consider its beta (a measure...

AUSTIN, Texas, Dec. 19, 2019 -- Molecular Templates, Inc., (Nasdaq: MTEM) a clinical-stage biopharmaceutical  company focused on the discovery and development of the Company’s.

Molecular Templates, Inc. (the “Company”) (MTEM) announced today that the 2020 Annual Meeting of Stockholders (the “Annual Meeting”) will be held virtually due to the public health impact of the novel coronavirus outbreak (COVID-19) and to support the health and well-being of the Company’s management and stockholders. As described in the proxy materials for the Annual Meeting previously distributed, stockholders as of the close of business on April 8, 2020, the record date, are entitled to participate in the Annual Meeting. In order to attend the Annual Meeting, stockholders must register in advance at www.proxydocs.com/MTEM prior to the deadline of May 26, 2020 at 5 p.m. Eastern Time.

Molecular Templates, Inc. (MTEM) (the “Company” or “Molecular”), a clinical-stage biopharmaceutical company focused on the discovery and development of the Company’s proprietary engineered toxin bodies (ETBs), which are differentiated, targeted, biologic therapeutics for cancer, today announced the pricing of its underwritten public offering of 6,000,000 shares of its common stock at a public offering price of $8.00 per share and 250 shares of its newly designated Series A convertible preferred stock at a public offering price of $8,000 per share. Each share of Series A convertible preferred stock will be convertible into 1,000 shares of common stock at the holder’s option, subject to beneficial ownership limitations. All of the shares of common stock and Series A convertible preferred stock to be sold in the offering are being sold by Molecular.

AUSTIN, Texas, May 13, 2020 -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery.

AUSTIN, Texas, Nov. 26, 2019 -- Molecular Templates, Inc. (Nasdaq: MTEM), a clinical-stage biopharmaceutical  company focused on the discovery and development of the Company’s.

Molecular Templates, Inc. (MTEM) (the “Company” or “Molecular”), a clinical-stage biopharmaceutical company focused on the discovery and development of the Company’s proprietary engineered toxin bodies (ETBs), which are differentiated, targeted, biologic therapeutics for cancer, today announced that it has commenced an underwritten public offering of its common stock and newly designated Series A convertible preferred stock. Molecular also intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering on the same terms and conditions. All of the shares in the offering are to be sold by Molecular.

As of late, it has definitely been a great time to be an investor Molecular Templates

We are still in an overall bull market and many stocks that smart money investors were piling into surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Hedge funds' top 3 stock picks returned 41.7% this year and beat […]

Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of the company’s proprietary engineered toxin bodies (ETBs), which are differentiated, targeted, biologic therapeutics for cancer and other serious diseases, today announced the initiation of dosing in a Phase I study investigating TAK-169 in patients with relapsed/refractory multiple myeloma. Co-developed with Takeda Pharmaceutical Company Limited (“Takeda”), TAK-169 is a potential first-in-class CD38-targeting ETB.

Molecular Templates, Inc., (MTEM) a clinical-stage biopharmaceutical company focused on the discovery and development of the Company’s proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), provided a corporate update and outlined expected 2020 milestones. “2019 was a year of growth for MTEM as we advanced our pipeline programs, established a new collaboration outside of oncology with a premier partner, and strengthened our balance sheet with a successful equity financing,” said Eric Poma, Ph.D., Chief Executive and Chief Scientific Officer of Molecular Templates.

Vertex Pharmaceuticals Incorporated (VRTX) and Molecular Templates, Inc. (Nasdaq: MTEM; “Molecular Templates” or “MTEM”) today announced that the two companies have entered into a strategic research collaboration to discover and develop novel targeted conditioning regimens that may enhance the hematopoietic stem cell transplant process, including transplants conducted as part of treatment with ex vivo CRISPR/Cas9 gene editing therapies such as CTX001. CTX001 is currently being evaluated in two ongoing Phase 1/2 studies in patients with transfusion-dependent beta thalassemia and severe sickle cell disease, where a hematopoietic stem cell transplant is required as part of treatment with CTX001.